- 501-1000 Employees
- Based in Gaithersburg, Maryland
Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant vaccines for infectious diseases using its virus-like particle platform (VLP) technology. It develops vaccine product candidates that target pandemic influenza, including H1N1 and H5N1 strains; seasonal influenza; and respiratory syncytial virus (RSV).
Most Recent Annual Report
2021 Annual Report and Form 10K
Novavax, Inc. does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.
Please fill out the form below and click "Place Order" to complete your order.
Older/Archived Annual Reports